<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146324</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-7CK</org_study_id>
    <nct_id>NCT04146324</nct_id>
  </id_info>
  <brief_title>An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia</brief_title>
  <official_title>A Prospective Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma in Australia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to estimate the effectiveness of nivolumab when given to participants
      after removing their cancer with surgery, over a 5-year follow-up, in real-world conditions
      in Australia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">July 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 9, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Relapse-Free Survival (RFS)</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
    <description>The time between the date of randomisation and the date of first recurrence, new primary melanoma, or death due to any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Distant Metastasis-Free Survival (DMFS)</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of sociodemographic profile of participants</measure>
    <time_frame>At treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of clinical characteristics of participants</measure>
    <time_frame>At treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prior medical history of participants</measure>
    <time_frame>At treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of nivolumab pattern of use</measure>
    <time_frame>At treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQOL) of participants as assessed by European Quality of Life Five Dimensional Scale (EuroQOL-5D/EQ-5D)</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL of participants as assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ C-30)</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL of participants as assessed by Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' socioeconomic status as assessed by their highest education level</measure>
    <time_frame>At treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of care received as assessed by Healthcare Resource Utlization</measure>
    <time_frame>During, and up to 5 years post discontinuation of nivolumab use</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing immune-related Adverse Events (AEs)</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing non-immune-related AEs</measure>
    <time_frame>Up to 5 years post treatment initiation with adjuvant nivolumab therapy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Adjuvant nivolumab therapy</arm_group_label>
    <description>Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Administered as adjuvant therapy as per the market authorization in Australia</description>
    <arm_group_label>Adjuvant nivolumab therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults whose melanoma had spread to the lymph nodes or other parts of the body and was
        surgically removed, and who are receiving post-surgery treatment with nivolumab to decrease
        the risk of cancer coming back.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with a primary diagnosis of melanoma with involvement of lymph nodes or
             metastatic disease who have undergone complete surgical removal and have no evidence
             of disease

          -  Decision to treat with adjuvant nivolumab therapy has already been taken

          -  Ability to provide written informed consent to participate in the study

        Exclusion Criteria:

          -  Adults with a current diagnosis of persisting advanced melanoma

          -  Adults currently enrolled in an interventional clinical trial for his/her melanoma
             treatment

        Other Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4012</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5001</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant</keyword>
  <keyword>nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

